{"filing":{"accession_number":"0001193125-26-299177","cik":"0001419041","ticker":"FBRX","company_name":"Forte Biosciences, Inc.","form":"8-K","filing_date":"2026-07-09","report_date":null,"primary_document":"d170175d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1419041/000119312526299177/d170175d8k.htm"},"events":[{"id":17212,"run_id":15398,"accession_number":"0001193125-26-299177","anchor_item_number":"7.01","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Forte Biosciences issued a press release on July 9, 2026 announcing positive Phase 1b clinical trial results for FB102 in vitiligo, including statistically significant efficacy endpoints (29.6% mean FVASI improvement, p=0.020) and safety data through week 24 post-treatment.","company_name":"Forte Biosciences, Inc.","ticker":"FBRX","filing_date":"2026-07-09","form":"8-K","submitted_at":null,"items":[{"id":15581,"accession_number":"0001193125-26-299177","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Forte Biosciences issued a press release on July 9, 2026 announcing positive Phase 1b clinical trial results for FB102 in vitiligo, including statistically significant efficacy endpoints (29.6% mean FVASI improvement, p=0.020) and safety data. While this is a clinical-stage biotech rather than a traditional earnings release, the disclosure of material clinical trial results through a press release furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure) constitutes a material event announcement comparable to an earnings release in structure and investor significance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:04:51.824210+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15582,"accession_number":"0001193125-26-299177","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Forte disclosed positive Phase 1b clinical trial results for FB102 in vitiligo, showing statistically significant improvements (29.6% mean FVASI improvement, p=0.020) and continued benefit through week 24 post-treatment. While this is a clinical milestone for a development-stage biopharmaceutical company, it does not fit the specific earnings_release category (which typically applies to financial results) nor any other defined event type. This is a material operational/clinical development event that would affect investor assessment of the company's pipeline progress and therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:04:51.824210+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15581,"accession_number":"0001193125-26-299177","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Forte Biosciences issued a press release on July 9, 2026 announcing positive Phase 1b clinical trial results for FB102 in vitiligo, including statistically significant efficacy endpoints (29.6% mean FVASI improvement, p=0.020) and safety data. While this is a clinical-stage biotech rather than a traditional earnings release, the disclosure of material clinical trial results through a press release furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure) constitutes a material event announcement comparable to an earnings release in structure and investor significance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:04:51.824210+00:00","company_name":"Forte Biosciences, Inc.","ticker":"FBRX","filing_date":"2026-07-09"},{"id":15582,"accession_number":"0001193125-26-299177","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Forte disclosed positive Phase 1b clinical trial results for FB102 in vitiligo, showing statistically significant improvements (29.6% mean FVASI improvement, p=0.020) and continued benefit through week 24 post-treatment. While this is a clinical milestone for a development-stage biopharmaceutical company, it does not fit the specific earnings_release category (which typically applies to financial results) nor any other defined event type. This is a material operational/clinical development event that would affect investor assessment of the company's pipeline progress and therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:04:51.824210+00:00","company_name":"Forte Biosciences, Inc.","ticker":"FBRX","filing_date":"2026-07-09"}]}